Class certification conundrum in the pharma field

Agreements between branded and generic drug makers for the latter to stay off the market for a certain period have become the basis for hundreds of “pay for delay” antitrust cases in the US; one observer opines that there may be more pending now than ever before.

Unlock unlimited access to all Global Competition Review content